Escalation After Three Years: Voting Against the Sustainability Committee Chair
A fund owns 1.9% of a European building materials company. For three years the team has engaged on Scope 3 cement emissions and capex alignment. The company has now set a 2030 Scope 1+2 target but excludes Scope 3, which is 78% of total emissions, and its capex plan includes a new 2.4 million tonne clinker line without carbon capture that the team calculates consumes 45% of the 2026–2030 capex budget. Two board seats are up at the May AGM, and the sustainability committee chair stands for re-election. The company offered a private meeting but declined to disclose the line's abatement plan, citing commercial sensitivity. A peer has asked the fund to join a collaborative engagement letter. The fund's policy allows voting against directors after three years of insufficient progress.
1. Is this the point to escalate to voting against the sustainability committee chair? Justify the sequencing and scope.
Read the worked answer
Yes - but against the committee chair only, not the whole board, and with a stated rationale tied to the specific decision.
Why the policy trigger is met: three years, partial progress (Scope 1+2 target), and the value-critical issue - a clinker line that locks in 45% of capex without an abatement pathway - remains undisclosed and unaddressed. Scope 3 exclusion means the target covers 22% of the footprint, so the 'progress' does not reach the material part.
Why the chair: accountability should attach to the board body with oversight of the capex-climate link. Voting against every director dilutes the signal and invites a 'box-ticking' response.
Why not divest yet: a 1.9% stake gives real access, the AGM is a dated lever, and the capex decision is not yet irreversible. Divestment forfeits the vote and the private channel.
Sequence: write to the chair setting out the specific ask (abatement plan for the line, Scope 3 baseline and target, capex alignment disclosure) and state the voting intention before the AGM. Vote against, and disclose the reason. Reassess after the capex FID.
2. The peer invites the fund to join a collaborative engagement letter. What are the benefits and the risks, and what conditions would you attach?
Read the worked answer
Benefits: greater leverage with a company that has stonewalled a single holder; lower cost per investor of research and meetings; a coordinated ask reduces the company's ability to play investors off each other; public letters can raise the cost of inaction.
Risks:
- MNPI: if the company shares the abatement plan in a collective setting, the group must have a protocol for handling non-public information; the fund should not trade while in possession.
- Antitrust/competition: avoid sharing competitively sensitive information (pricing, volumes, contract terms) among participants; keep coordination to the ESG ask.
- Free-riding and dilution: a broad letter can soften the message; sign-on terms should preserve the specific asks.
- Attribution: the fund must be able to report its own escalation and votes separately from the group's activity.
Conditions: agreed asks and escalation timetable in writing; a named lead and disclosure protocol; no joint public statement without sign-off; the fund retains its independent voting decision. Joining the letter does not replace the vote - they are complementary levers.
3. How would you define and record success so the engagement is not reported as a vague win?
Read the worked answer
Define milestones before the next review, and record status against each - success is a movement in a milestone, not a meeting held.
Milestones:
- Scope 3 baseline and a 2030 target covering the 78%.
- A published abatement plan for the new clinker line, including CCS feasibility and cost per tonne.
- Capex disclosure reconciling the 45% allocation to the company's stated transition pathway.
- Board-level accountability: a named director responsible, and capex-climate competence on the committee.
Recording: use a fixed taxonomy - achieved / partial / no change / escalated / closed - with the evidence and date. Note the vote against the chair as an escalation, not a failure. Record that the company declined disclosure, since refusal is an outcome.
What success is not: 'targets set' when the target excludes the material emissions; or attributing a share-price move to engagement. State the counterfactual honestly and avoid claiming causality the fund cannot evidence.